Sakhanda Wire
NVDA $152.86 -2.10% MSFT $505.56 -2.40% GOOGL $280.34 -1.19% META $618.69 -1.23% AMZN $256.63 -0.43%
← Back to the news

Enveda raises $311 million for AI-discovered drugs

Enveda, a biotech startup applying artificial intelligence to drug discovery from plants and microbes, has raised $311 million in a Series E funding round. The financing values the company at $2 billion, twice its valuation 12 months earlier. Catalio Capital Management led the round, with participation from Iconiq and other investors.

The company was founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals. Enveda aims to identify potential medicines from natural sources and accelerate their development with AI and other methods, rather than creating compounds entirely through laboratory synthesis.

AI has not yet produced a drug approved by the FDA, but Enveda is among the companies moving AI-discovered candidates into human testing. Its current clinical programs include several medicines being tested in patients, including a treatment intended for severe skin conditions and another designed to help people maintain weight loss after stopping GLP-1s.

Written by Sakhanda Wire AI from reporting by TechCrunch. Facts, quotes and full context are in the original article below.

Originally published by TechCrunch on

Read the original on TechCrunch ↗

The reporting and the image belong to TechCrunch and are credited and linked above; the text on this page is Sakhanda Wire's own summary.

← Back to the news

More stories

All the latest news